logo
Plus   Neg
Share
Email

Cisco Inks Strategy Document Outlining R&D Plans With Skolkovo Foundation

Cisco (CSCO) has signed a strategy document outlining its Research and Development plans with the Skolkovo Foundation, marking an important milestone in Cisco's multi-year, $1 billion investment in sustainable innovation within the Russian Federation. The company said that the plan sets the way for to create a physical R&D presence in the Skolkovo Technopolis, and was announced at the Global Technology Symposium, in Menlo Park, California.

Cisco noted that the strategy reinforces its investment in the Skolkovo Project, an initiative supported by President Medvedev to create a technology and innovation hub on the outskirts of Moscow. Recently, the company received formal Skolkovo participant status, which enables the company to begin engineering activities and formally establish a physical presence.

Cisco targets to focus R&D in Skolkovo on high-impact areas of the business, including video and internal start-ups, using Skolkovo as the physical and virtual platform for innovation, which would contribute to transforming Skolkovo into one of the most advanced technology regions in the world.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Billionaire entrepreneur Elon Musk on Thursday showed off his concept for the Loop, a high-speed underground public transportation system that will carry up to 16 people and travel at 150 miles per hour. At the Boring Company Information Session, Musk and project leader Steve Davis provided details of the underground mass transit tunnels that the Boring Co. plans to build beneath Los Angeles. Raden has become the second smart luggage company to shut down this month after major U.S. airlines banned smart luggage with non-removable batteries earlier this year. In a statement on its website, Raden said that it is no longer in operation and that all existing shipments have been processed for delivery. The company is shuttering after three years of operation. Shares of AstraZeneca were losing around 2 percent in the London trading after the British drug major reported Friday lower profit in its first quarter amid weak margin, despite growth in product sales. Further, the company reiterated its outlook for fiscal 2018. The level of Externalisation Revenue, divestment timing and investment in launches impacted the overall results.
Follow RTT